OH-PROCTER-&-GAMBLE
10.6.2020 15:02:07 CEST | Business Wire | Press release
This week, P&G Beauty convened a virtual meeting with leading global NGOs to discuss the role of the beauty industry in accelerating progress towards a more sustainable, inclusive and resilient future.
Until now, the industry has responded to consumer concerns over safety, quality, origin and sustainability with an array of claims – such as natural, organic or clean – many of which lack clear definitions and standards and are sometimes at odds with one another. The group made up of experts from various NGOs and Alex Keith, CEO, P&G Beauty, recognized that it is more vital than ever to look at these challenges as interconnected rather than individually. For the industry to become future-fit and to build business resilience, the group concluded that it must address systemic challenges through collective action, leveraging the best of science and protecting nature by purposefully bringing the two together.
P&G Beauty is addressing this through its P&G Responsible Beauty platform , a systems-thinking approach rooted in the connections and interdependence of five guiding principles: Quality & Performance; Safety; Sustainability; Transparency, and Equality & Inclusion. As part of the event, P&G Beauty shared the P&G Responsible Beauty 2030 goals (link ). One of the goals of P&G Responsible Beauty is openly sharing technologies, programs or processes that can help the beauty industry have a bigger, positive impact on the world. As a tangible first action to bring this goal to life the Company is making publicly available a comprehensive guide for the safe use of botanicals in beauty products (link ). The guide, incorporating learnings from over a decade of published research, provides formulators from small to large size beauty brands, with a robust safety approach to assess botanical ingredients and ensure their safe use in products.
The event, co-hosted by Women’s Wear Daily, was attended by media representatives from around the world, and featured P&G Beauty CEO Alex Keith and the P&G Responsible Beauty Advisory Council, an advisory group created more than a year ago to ensure P&G Beauty priorities are well informed by the most innovative, leading-edge thinking and experience. The Council is made up of representatives from Royal Botanic Gardens, Kew (a world leading authority on plant science); World Wildlife Fund (WWF); Rainforest Alliance; Skin Health Alliance; and the Roundtable on Sustainable Biomaterials.
“Making meaningful progress via responsible growth – growth rooted in systems thinking - requires partnership and collaboration,” said Alex Keith, CEO of P&G Beauty, “The P&G Responsible Beauty Advisory Council helps to ensure we are bringing external insights and experience into our decision-making, and applying systems thinking to our plans to ensure we consider the interdependencies of one choice on other critical areas.”
The panel discussion during the event covered a range of topics underscoring the extent to which human health and economic prosperity depend on a healthy, natural world, as well as how systems thinking can help the beauty industry navigate and understand today’s disruptions and provide solutions to build back better in a post-COVID world via a focus on responsible growth.
“Building business resilience in a way that supports a sustainable world, improves quality of life, respects human rights and protects the environment is possible,” said P&G Beauty’s Keith. "For beauty, this means going beyond environmental practices to address the interdependence of all aspects of product development and corporate behavior — all activities that affect the beauty consumer and the world in which we live.”
# # #
About the P&G Responsible Beauty Advisory Council Members:
Rainforest Alliance // Rainforest-alliance.org
The Rainforest Alliance works at the intersection of business, agriculture and forests to make “responsible business” the new normal, protecting forests and improving the lives of farmers and forest communities.
Roundtable on Sustainable Biomaterial // Rsb.org
The Roundtable on Sustainable Biomaterials (RSB) guides the responsible development and production of biomass, biofuels, and biomaterials through sustainability solutions, certification, and collaborative partnerships.
World Wildlife Fund // worldwildlife.org
For almost 60 years, the WWF has been protecting the future of nature. One of the world’s leading conservation organizations, WWF develops solutions to help communities and wildlife thrive.
Royal Botanic Gardens, Kew // kew.org
The global resource for plant and fungal research, the Royal Botanic Gardens, Kew uses their unparalleled expertise, botanical collections, and global partnerships to tackle the critical challenges facing humanity.
Skin Health Alliance // skinhealthalliance.org
The Skin Health Alliance collaborates with dermatologists, researchers and skin scientists to provide independent, scientifically based verification of the safety of beauty products, clinics, treatments, and services.
About P&G:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
For more information:
https://us.pg.com/responsible-beauty/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005452/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom